Every Form 4 that ANI Pharmaceuticals, Inc. (ANIP) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ANIP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ANIP filings page.
ANI PHARMACEUTICALS INC (ANIP) reports that President and CEO Nikhil Lalwani sold 5,400 shares of common stock on September 15, 2026 at $71.00 per share, for about $383,400 in total proceeds. After this transaction, he directly holds 339,089 shares. The sale was effected under a Rule 10b5-1 trading plan adopted on May 26, 2026.
ANI PHARMACEUTICALS INC (ANIP) director Jeanne Thoma reported selling 1,000 shares of common stock on September 11, 2026 at $71.53 per share in an open-market or private transaction. After this sale, she directly holds 26,762 shares. The sale was effected under a Rule 10b5-1 trading plan adopted on June 12, 2026.
ANI PHARMACEUTICALS INC (ANIP) insider Meredith Cook, Senior Vice President, General Counsel & Secretary, reported selling 500 shares of common stock on September 14, 2026 at $70.79 per share. After this transaction, she directly holds 73,924 shares of ANI Pharmaceuticals common stock.
The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025, indicating the trade was made under a pre-arranged plan.
ANI PHARMACEUTICALS INC (ANIP) disclosed that SVP & CFO Stephen P. Carey sold 2,850 shares of common stock on 2026-08-31 at a weighted average price of $72.80 per share, in trades ranging from $71.89 to $73.36, pursuant to a Rule 10b5-1 trading plan. Following this sale, he directly holds 171,843 shares of ANI common stock.
ANI PHARMACEUTICALS INC (symbol: ANIP) is the issuer of record for a Form 4 filing submitted to the SEC.
ANI PHARMACEUTICALS INC (ANIP) reported that President & CEO Nikhil Lalwani sold 5,400 shares of common stock on August 25, 2026 in an open-market or private transaction at a weighted average price of $74.30 per share, with trades ranging from $73.58 to $74.61. The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 26, 2026. Following this sale, Lalwani directly holds 344,489 shares of ANIP common stock.
ANI Pharmaceuticals Inc. insider Meredith Cook, Senior Vice President, General Counsel and Secretary, reported a sale of 500 shares of common stock on August 13, 2026 at $75.48 per share. After this transaction, Cook directly holds 74,424 shares of ANI Pharmaceuticals common stock. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on September 15, 2025.
ANI Pharmaceuticals Inc. senior vice president of generics Ori Gutwerg reported a sale of 3,162 shares of common stock on 2026-08-10 at $77.00 per share in an open market or private transaction. After this sale, he directly holds 75,534 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals SVP & CFO Stephen P. Carey sold 2,850 shares of common stock on July 29, 2026 at a weighted average price of $81.36 per share in open-market or private transactions. The trades, priced between $80.61 and $81.88, were executed under a Rule 10b5-1 trading plan adopted on March 6, 2026. Following the sale, Carey directly holds 174,693 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals reported that executive Meredith Cook, Sr. VP, General Counsel & Secretary, had 2,466 shares of common stock withheld on July 18, 2026 to cover tax obligations, at $79.20 per share. The withholding related to the vesting of 4,820 restricted shares. Following this transaction, Cook directly holds 74,924 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals Inc. reported that senior vice president, general counsel and secretary Meredith Cook completed an open-market sale of 500 shares of common stock on July 13, 2026 at $81.84 per share. The transaction was executed under a Rule 10b5-1 trading plan adopted on September 15, 2025, and Cook now directly holds 77,390 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals SVP & CFO Stephen P. Carey exercised options and sold shares in a planned transaction. On July 2, 2026, he exercised a stock option for 3,313 shares of common stock at $49.51 per share and sold 3,313 shares in an open-market transaction at $86 per share. The exercise and sale were made under a Rule 10b5-1 trading plan adopted on March 6, 2026. Following these transactions, he directly holds 177,543 shares of ANI Pharmaceuticals common stock. The option had vested in four 25% installments on March 31 of 2018, 2019, 2020, and 2021 and carries an expiration date of March 30, 2027.
ANI Pharmaceuticals SVP & CFO Stephen P. Carey reported an open-market sale of 2,850 shares of common stock at a weighted average price of $84.12 per share. After the sale, he directly holds 177,543 shares, indicating that the transaction represents a small portion of his overall stake.
The trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 6, 2026, and occurred in multiple transactions at prices ranging from $83.39 to $84.63. Such plans are designed to allow insiders to sell shares over time according to preset instructions.
ANI Pharmaceuticals senior vice president, general counsel and secretary Meredith Cook reported an open-market sale of 500 shares of Common Stock. The shares were sold at an average price of $82.03 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 15, 2025. After this sale, Cook directly held 77,890 shares of ANI Pharmaceuticals common stock.
Thoma Jeanne reported acquisition or exercise transactions in this Form 4 filing.
ANI Pharmaceuticals director Jeanne Thoma received a new equity grant. She was awarded 4,357 shares of ANI Pharmaceuticals common stock as a restricted stock award, with no cash paid per share. After this grant, she directly holds 27,762 common shares.
The restricted stock award will vest in full on May 21, 2027, meaning she will gain full ownership of these shares on that date if the vesting conditions are satisfied.
TANNENBAUM RENEE P reported acquisition or exercise transactions in this Form 4 filing.
ANI Pharmaceuticals director Renee P. Tannenbaum received a grant of 4,357 shares of common stock as a restricted stock award on May 21, 2026. The award carries no purchase price and will vest in full on May 21, 2027, if conditions are met.
Following this compensation-related grant, Tannenbaum directly holds 29,514 shares of ANI Pharmaceuticals common stock. This is a routine equity award to a board member rather than an open-market transaction.
Pera Antonio R reported acquisition or exercise transactions in this Form 4 filing.
ANI Pharmaceuticals director Antonio R. Pera received a grant of 4,357 shares of Common Stock as a restricted stock award. The award was granted at no cash cost to him and is part of his equity compensation.
The restricted shares are scheduled to vest in full on May 21, 2027, meaning they must be held until that date before becoming fully transferable. Following this grant, Pera directly holds a total of 27,017 shares of ANI Pharmaceuticals Common Stock.
Leonard Matthew J reported acquisition or exercise transactions in this Form 4 filing.
ANI Pharmaceuticals director Matthew J. Leonard received a grant of 4,357 shares of common stock as a restricted stock award. The award was granted at no cash cost per share and is part of his equity-based compensation. These restricted shares will vest in full on May 21, 2027, meaning he must remain eligible through that date to receive them outright. After this grant, Leonard directly holds a total of 11,221 shares of ANI Pharmaceuticals common stock, indicating this is a relatively small, routine compensation-related award rather than a market purchase or sale.
ANI Pharmaceuticals director Thomas Haughey reported both a stock grant and a share sale. On May 21, 2026, he acquired 4,357 shares of Common Stock as a restricted stock award that will vest in full on May 21, 2027. On June 8, 2026, he sold 2,000 Common Stock shares in an open-market transaction at $80.88 per share under a pre-arranged Rule 10b5-1 trading plan adopted on March 9, 2026. After these transactions, he directly holds 38,878 Common Stock shares.
ANI Pharmaceuticals SVP & CFO Stephen P. Carey reported an option exercise and share sale. He exercised stock options to acquire 3,312 shares of common stock at $49.51 per share, then sold 3,312 shares in an open-market transaction at $80.00 per share. The transactions were completed under a pre-arranged Rule 10b5-1 trading plan. After these trades, Carey directly owns 180,393 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals director Patrick D. Walsh reported selling Common Stock in two open-market transactions. On May 13, he sold 10,000 shares at an average price of $80.63 per share. On May 11, he sold an additional 3,973 shares at an average price of $80.75 per share. After these sales totaling 13,973 shares, Walsh directly holds 38,432 shares of ANI Pharmaceuticals Common Stock.
ANI Pharmaceuticals senior vice president Thomas Andrew Rowland reported an open-market sale of company stock. He sold 459 shares of Common Stock at $79.21 per share on May 12, 2026. After this transaction, he directly holds 38,271 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals President and CEO Nikhil Lalwani reported an open-market sale of 55,000 shares of Common Stock on May 11, 2026, at a weighted average price of $77.57 per share. The shares were sold in multiple trades at prices ranging from $76.21 to $80.38. Following this transaction, Lalwani directly holds 349,889 shares of ANI Pharmaceuticals Common Stock.
ANI Pharmaceuticals senior vice president of generics Ori Gutwerg reported an open-market sale of Common Stock. On May 12, 2026, he sold 2,772 shares at a price of $79.50 per share. After this transaction, he directly owns 78,696 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals Inc. senior vice president, general counsel and secretary Meredith Cook reported an open-market sale of 500 shares of common stock at $78.16 per share. The transaction occurred on May 13, 2026 and was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 15, 2025.
After this sale, Cook directly holds 78,390 shares of ANI Pharmaceuticals common stock, indicating she retains a substantial equity position in the company despite the relatively small disposition.
ANI Pharmaceuticals senior vice president Meredith Cook sold a small block of company stock in a pre-planned trade. Cook executed an open-market sale of 500 shares of ANI Pharmaceuticals common stock at $77.95 per share. After this transaction, she continues to hold 78,890 shares directly, indicating she retains the vast majority of her stake. The sale was carried out under a Rule 10b5-1 trading plan adopted in advance, which means the trade was pre-scheduled rather than timed discretionarily.
ANI Pharmaceuticals senior executive sells part of stake
ANI Pharmaceuticals’ SVP, Head – Established Brands, Thomas Andrew Rowland, reported an open-market sale of 4,772 shares of common stock at an average price of $74.91 per share. After this transaction, he directly holds 38,730 shares, indicating a partial sale while retaining a significant remaining position.
ANI Pharmaceuticals executive Christopher Mutz, Head of Rare Disease, reported an open-market sale of 3,162 shares of Common Stock. The shares were sold on March 13, 2026 at a weighted average price of $71.64 per share, in multiple trades ranging from $70.27 to $72.62.
The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 16, 2025. Following this sale, Mutz directly holds 91,309 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals senior vice president and general counsel Meredith Cook reported a small open-market sale of 500 shares of common stock at $72.62 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 15, 2025.
After this sale, Cook still directly owns 79,390 shares, so the trade represents a minor portion of her overall reported holdings and appears to be a routine, pre-planned liquidity event rather than a major change in ownership.
ANI Pharmaceuticals executive Christopher Mutz reported recent stock transactions in ANI PHARMACEUTICALS INC common shares. He sold 2,121 shares on March 6, 2026 at $74.22 per share and 3,602 shares on March 9, 2026 at $74.18 per share, both as open‑market sales under a Rule 10b5‑1 trading plan adopted on June 16, 2025. Separately, 3,314 shares were withheld on March 7, 2026 at $74.04 per share to cover tax obligations tied to the vesting of 6,476 restricted shares. After these transactions, he directly holds 94,471 shares of ANI common stock.
ANI Pharmaceuticals President & CEO Nikhil Lalwani reported a tax-related share disposition. On the reported date, 17,060 shares of common stock were withheld at a price of $74.04 per share to cover tax obligations tied to the vesting of 33,352 previously granted restricted shares.
These withheld shares were not an open-market sale but a payment of tax liability. After this withholding, Lalwani directly owned 404,889 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals SVP, Generics Ori Gutwerg had 3,314 shares of Common Stock withheld on March 7, 2026 to cover tax obligations at $74.04 per share. The shares were tied to the vesting of 6,476 restricted shares, and Gutwerg now holds 81,468 shares directly.
ANI Pharmaceuticals senior executive Krista Davis reported open-market sales of company stock. As SVP and Chief HR Officer, she sold 6,572 shares of ANI Pharmaceuticals common stock in two transactions at prices of $74.13 and $75.00 per share. These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 18, 2025, indicating they were scheduled in advance rather than timed discretionarily. Following the transactions, Davis directly holds 51,946 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals SVP & CFO Stephen P. Carey reported a tax-related share disposition. On the vesting of 11,292 shares of restricted stock that had been granted earlier, 5,150 shares of common stock were withheld at $74.04 per share to cover tax obligations, a non-market transaction exempt under Rule 16(b)-3. After this withholding, Carey directly holds 180,393 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals senior vice president and CFO Stephen P. Carey reported both an option exercise and share sales. He exercised options for 3,312 shares at $49.51 per share, then sold a total of 7,312 common shares in open‑market trades at prices around $75.42–$75.56. Following these transactions, he directly holds 185,543 shares of common stock and 9,938 stock options.
ANI Pharmaceuticals reported that Christopher Mutz, its Head of Rare Disease, sold 417 shares of common stock in an open-market transaction at $74 per share. After this sale, he directly owns 103,508 shares. The sale was made under a pre-established Rule 10b5-1 trading plan adopted by the reporting person.
ANI Pharmaceuticals senior vice president Ori Gutwerg reported an open-market sale of company stock. On March 3, 2026, he sold 2,060 shares of Common Stock at a price of $76.50 per share. After this transaction, he directly owned 84,782 common shares.
ANI Pharmaceuticals director Patrick D. Walsh reported an open-market sale of 6,000 shares of common stock at $74.23 per share on March 3, 2026. After this transaction, he directly holds 52,405 shares.
Shanmugam Muthusamy reported acquisition or exercise transactions in this Form 4 filing.
ANI Pharmaceuticals director and executive Shanmugam Muthusamy received a grant of 11,116 shares of common stock as a restricted stock award. The award was granted on February 26, 2026 at $77.15 per share and will vest in four equal annual installments on the first, second, third and fourth anniversaries of that date.
After this grant, he directly holds 101,056 common shares. He also has indirect ownership over 431,920 shares held by Esjay LLC and 5,000 shares held by SS Pharma LLC, where he holds voting and dispositive power over the shares.
ANI Pharmaceuticals executive Thomas Andrew Rowland, SVP and Head of Established Brands, reported equity compensation activity in company common stock. On February 26, 2026, he acquired 6,021 shares as a restricted stock award at $77.15 per share. This award will vest in four equal annual installments on the first through fourth anniversaries of February 26, 2026.
On February 28, 2026, 628 shares were disposed of at $73.90 per share to cover tax withholding in connection with the vesting of 2,171 previously granted restricted shares. After these transactions, he directly holds 43,502 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals executive Christopher Mutz reported two equity-related transactions in company stock. On February 26, 2026, he acquired 21,306 shares of common stock through a restricted stock award that will vest in four equal annual installments on each anniversary of February 26, 2026.
On February 28, 2026, 2,221 shares of common stock were disposed of to cover tax withholding in connection with the vesting of 4,342 previously granted restricted shares, a transaction exempt under Rule 16(b)-3. After these transactions, Mutz directly owned 103,925 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals President and CEO Nikhil Lalwani reported two equity compensation events involving the company’s common stock. On February 26, 2026, he acquired 75,592 shares through a restricted stock award at $77.15 per share. According to the footnotes, this award will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 26, 2026, tying his compensation to multi‑year performance.
On February 28, 2026, Lalwani had 12,217 shares withheld at $73.90 per share as a tax-withholding disposition in connection with the vesting of 23,883 previously granted restricted shares. These shares were withheld for tax purposes and are exempt under Rule 16(b)-3, rather than being an open-market sale. After these transactions, his directly owned common stock holdings were reported at 434,166 shares following the award and 421,949 shares following the tax withholding.
ANI Pharmaceuticals senior vice president of generics, Ori Gutwerg, reported two equity-related transactions in common stock. On February 26, 2026, he acquired 12,969 shares at $77.15 per share as a grant or award, bringing his direct holdings to 89,063 shares. According to a footnote, this restricted stock award will vest in four equal annual installments on the first, second, third, and fourth anniversaries of February 26, 2026.
On February 28, 2026, 2,221 shares were disposed of at $73.90 per share in a tax-withholding disposition related to the vesting of 4,342 previously granted restricted shares, leaving Gutwerg with 86,842 directly owned shares.
ANI Pharmaceuticals SVP Chad Gassert reported equity compensation and related tax withholding transactions in company stock. On February 26, 2026, he acquired 11,116 shares of common stock as a restricted stock award at $77.15 per share, scheduled to vest in four equal annual installments on the first through fourth anniversaries of February 26, 2026.
On February 28, 2026, 2,221 shares were withheld at $73.90 per share to cover taxes tied to the vesting of 4,342 previously granted restricted shares, leaving 74,916 shares held directly. He also has indirect ownership of 158,490 shares held by Chali Properties LLC, over which he holds voting and dispositive power.
ANI Pharmaceuticals senior vice president and chief HR officer Krista Davis reported two stock transactions involving company common shares. On February 26, 2026, she acquired 10,810 shares through a restricted stock award at $77.15 per share, bringing her direct holdings to 60,073 shares. This award is scheduled to vest in four equal annual installments on the first, second, third, and fourth anniversaries of February 26, 2026. On February 28, 2026, 1,555 shares were withheld at $73.90 per share to cover tax obligations related to the vesting of a prior restricted stock grant, leaving her with 58,518 directly owned shares. The tax withholding is characterized as a payment of tax liability by delivering securities, not an open-market sale.
ANI Pharmaceuticals senior vice president and general counsel Meredith Cook reported equity compensation activity in company stock. On February 26, 2026, Cook acquired 13,895 shares of common stock as a restricted stock award at $77.15 per share, which will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 26, 2026. On February 28, 2026, 1,555 shares at $73.90 per share were disposed of through shares withheld for tax purposes in connection with the vesting of 3,040 previously granted restricted shares. After these transactions, Cook directly owned 79,890 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals SVP & CFO Stephen P. Carey reported two equity transactions in company common stock. On February 26, 2026, he received a grant of 22,233 restricted shares at $77.15 per share, which will vest in four equal annual installments starting on the first anniversary of that date. On February 28, 2026, 2,773 shares at $73.90 per share were disposed of for tax withholding in connection with the vesting of 6,079 previously granted restricted shares. After these transactions, he directly owned 189,543 common shares.
ANI Pharmaceuticals executive Christopher Mutz reported an open-market sale of company stock. On the reported date, he sold 5,323 shares of ANI Pharmaceuticals common stock at a weighted average price of $78.02 per share, with individual trade prices ranging from $77.20 to $78.58.
The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 16, 2025. After this sale, Mutz directly holds 84,840 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals senior vice president and chief human resources officer Krista Davis sold a total of 3,814 shares of Common Stock in open‑market transactions. She sold 2,084 shares at a weighted average price of $77.53 on February 19, 2026 and 1,730 shares at $77.99 on February 20, 2026. The sales were executed under a Rule 10b5‑1 trading plan adopted on September 18, 2025, and she held 49,263 shares directly after the most recent sale.
Rowland Thomas Andrew reported disposition transactions in a Form 4 filing for ANIP. The filing lists transactions totaling 1,051 shares at a weighted average price of $77.00 per share. Following the reported transactions, holdings were 38,109 shares.